SPECTROSCOPIC DIAGNOSIS OF MELANOMA

• Research type

  Research Study

• Full title

  Developing Spectroscopic Biofluid Diagnosis, Monitoring and Therapeutic Profiling of Melanoma Patients

• IRAS ID

  177519

• Contact name

  RUTH BOARD

• Contact email

  ruth.board@lthtr.nhs.uk

• Sponsor organisation

  Lancashire Teaching Hospitals NHS Foundation Trust

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  The purpose of this study is to find out whether there are changes in blood samples of patients with melanoma that can be detected with spectroscopy. Spectroscopy is a method that uses light shone into a blood sample to detect minute changes in chemicals and molecules within a sample. Blood samples will be taken from patients with various staging of melanoma to assess whether blood based spectroscopy signatures can be used to detect metastatic disease, spread of disease to the brain and response to treatment. These changes will be compared to changes in the tissue samples.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  15/LO/1312

• Date of REC Opinion

  20 Jul 2015

• REC opinion

  Favourable Opinion